以上海信谊百路达药业有限公司生产的甲磺酸多沙唑嗪缓释片为受试制剂，以持证商为Viatris Pharma GmbH的甲磺酸多沙唑嗪缓释片（商品名：可多华®）为参比制剂，按生物等效性试验的相关规定，比较两种制剂在中国健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。评价中国健康受试者单次空腹/餐后口服受试制剂和参比制剂后的安全性。

[Translation]

The doxazosin mesylate sustained-release tablets produced by Shanghai Xinyi Bailuda Pharmaceutical Co., Ltd. were used as the test preparation, and the doxazosin mesylate sustained-release tablets (trade name: Keduohua®) produced by the licensee Viatris Pharma GmbH were used as the reference preparation. According to the relevant provisions of the bioequivalence test, the pharmacokinetic behavior of the two preparations in healthy Chinese subjects was compared to evaluate the bioequivalence of the two preparations. The safety of the test preparation and the reference preparation after a single oral administration on an empty stomach or after a meal was evaluated in healthy Chinese subjects.

Start Date18 Mar 2025

Sponsor / Collaborator

Shanghai Xinyi Bailuda Pharmaceutical Co. Ltd.

CTR20244490

/ CompletedNot Applicable

甲磺酸多沙唑嗪缓释片（4mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两制剂、两序列、两周期、双交叉生物等效性试验

[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period, double-crossover bioequivalence study of doxazosin mesylate extended-release tablets (4 mg) in Chinese healthy subjects under fasting and fed conditions

主要研究目的：按有关生物等效性试验的规定，选择Pfizer OFG Germany GmbH持证的甲磺酸多沙唑嗪缓释片（商品名：可多华®，规格：4mg）为参比制剂，对常州制药厂有限公司生产的受试制剂甲磺酸多沙唑嗪缓释片（规格：4mg）进行空腹和餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评价两种制剂在空腹和餐后给药条件下的生物等效性。次要研究目的：观察健康受试者口服受试制剂甲磺酸多沙唑嗪缓释片（规格：4mg）和参比制剂甲磺酸多沙唑嗪缓释片（商品名：可多华®，规格：4mg）的安全性。

[Translation]

Main purpose of the study: According to the relevant provisions of bioequivalence test, Pfizer OFG Germany GmbH's certified doxazosin mesylate sustained-release tablets (trade name: Kadova®, specification: 4 mg) were selected as the reference preparation, and the test preparation doxazosin mesylate sustained-release tablets (specification: 4 mg) produced by Changzhou Pharmaceutical Factory Co., Ltd. were subjected to fasting and postprandial human bioequivalence tests to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose of the study: To observe the safety of oral administration of the test preparation doxazosin mesylate sustained-release tablets (specification: 4 mg) and the reference preparation doxazosin mesylate sustained-release tablets (trade name: Kadova®, specification: 4 mg) by healthy subjects.

Start Date23 Dec 2024

Sponsor / Collaborator

Changzhou Pharmaceutical Factory Co., Ltd.

ChiCTR2400088971

/ Not yet recruitingPhase 1IIT

Randomized controlled clinical study on the improvement of symptoms of chronic prostatitis/chronic pelvic pain syndrome by extracorporeal shortwave therapy device

Start Date01 Sep 2024

Sponsor / Collaborator

Xiangya Hospital Central South University

100 Clinical Results associated with Doxazosin Mesylate

100 Translational Medicine associated with Doxazosin Mesylate

100 Patents (Medical) associated with Doxazosin Mesylate

2,131

Literatures (Medical) associated with Doxazosin Mesylate

28 Jan 2026·ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Photochemical Deracemization of Chromanes and its Application to the Synthesis of Enantiopure Bioactive Compounds

Article

Author: Pauls, Mike ; Bannwarth, Christoph ; Iglhaut, Maximilian ; Ghosh, Biki ; Babushkina, Daria ; Bach, Thorsten

Abstract:

Chromanes are frequently encountered as chiral structure elements in active pharmaceutical ingredients (APIs). We have now discovered an access to enantiopure chromanes, which employs a 1:1 mixture of their enantiomers (racemate) in a photochemical deracemization reaction (21 examples, 71%–90% yield, 80%–99% ee ). A chiral photocatalyst (10 mol%) acts by selective hydrogen abstraction at one chromane enantiomer and establishes a photostationary state in which the other enantiomer prevails. A thiol additive (20 mol%) was found to improve the enantioselectivity of the process. The mechanism of the reaction was investigated by experimental and quantum‐chemical studies. The oxygen atom of the chromane locks the rotation around the exocyclic C─C bond to the amide by forming an intramolecular hydrogen bond. Forward hydrogen atom transfer (HAT) occurs exclusively in one diastereomeric complex via a readily accessible transition state. Reasonable pathways for back HAT were identified which are in line with deuterium labeling experiments. The method was applied to the concise preparation of five chromane‐containing drugs (Doxazosin, Fidarestat, Nebivolol, Repinotan, Sarizotan) as single enantiomers.

02 Jan 2026·Arab Journal of Urology

Efficacy of alpha-blockers in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials between 2010 and 2025

Review

Author: Almurshed, Oroub Abdulaziz ; Alshammari, Adel H. ; Alsulami, Yazeed Dakhel ; Alkharboosh, Abdullah Sulaiman ; Alruhaili, Wijdan Ateeq Allah ; Alotaibi, Eman Abdullah ; Alomari, Renad Wesam ; Alotaibi, Mohammed Saad ; Almaghthawi, Mohammed Marzouq ; Alahamdi, Manar Ali ; Aljaddua, Salem Ibrahim S ; Hijazi, Eyad Mohammed

Introduction:

Alpha-blockers are widely used in medical expulsive therapy (MET) for ureteral stones; however, the current evidence regarding their comparative effectiveness remains inconsistent. We aimed to evaluate the efficacy and safety of different alpha-blockers in facilitating ureteral stone passage and identify factors influencing treatment outcomes.

Methods:

We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) published between 2010 and 2025. We searched multiple databases for studies comparing alpha-blockers with control interventions or other alpha-blockers for ureteral stones ≤10 mm. Primary outcome was stone expulsion rate; secondary outcomes included time to expulsion, pain episodes, analgesic use, and adverse events. We performed subgroup analyses by alpha-blocker type, stone size, location, and treatment duration. Network meta-analysis assessed comparative effectiveness between agents.

Results:

Twenty-nine RCTs with a total of 4,256 patients were included. Alpha-blockers significantly increased stone expulsion rates compared to controls (70.9% vs. 56.5%; RR 1.25, 95% CI 1.20-1.32; Number Needed to Treat (NNT) = 7) and reduced expulsion time by approximately three-days. Efficacy was greatest for distal ureteral stones (RR 1.52; Number Needed to Treat (NNT) = 4) and stones 5-10 mm (RR 1.35; NNT = 6). Network meta-analysis revealed efficacy ranking favoring at first terazosin, followed by doxazosin then, silodosin then, tamsulosin then, alfuzosin and last the least effective was naftopidil. Alpha-blockers significantly reduced pain episodes and analgesic requirements. Adverse events were infrequent (Number Needed to Harm (NNH) = 38), with retrograde ejaculation being most common with silodosin.

Conclusion:

Alpha-blockers significantly improve the stone expulsion rates and reduce expulsion time, especially for distal ureteral stones 5-10 mm in size. While tamsulosin remains the most studied agent, our network meta-analysis suggests terazosin and doxazosin may offer superior efficacy. The favorable risk-benefit profile supports routine use of alpha-blockers for appropriately selected patients with ureteral stones.

31 Dec 2025·International Neurourology Journal

Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis

Article

Author: Nathania, Nathania ; Lionardi, Stevan Kristian ; Wilyono, Agoes ; Supinto, Pedro Arruda ; Rinaldi, Fransiskus Xaverius ; Silalahi, Parningotan Yosi ; Niaga, Karmenia Jessica Kurnia ; Yo, Rivan

Purpose: Alpha-blockers and 5-alpha reductase inhibitors (5ARIs) are well-established treatments for symptoms of benign prostatic hyperplasia (BPH). Despite their therapeutic benefits, concerns have been raised regarding a potential association between these medications and an increased risk of dementia. However, current evidence remains inconsistent, highlighting the need for further evaluation. This study aims to assess the potential dementia risk among patients receiving alpha-blockers and 5ARIs.Methods: Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines (PROSPERO CRD42025643431), 7 databases were systematically searched through December 2024 for studies examining the association between alpha-blockers or 5ARIs and dementia risk in patients with BPH. Risk of bias was assessed using the ROBINS-I (Risk of Bias in Non-randomized Studies of Interventions) tool. A Bayesian network meta-analysis was performed to estimate risk ratios with 95% credible intervals and to generate surface under the cumulative ranking curve (SUCRA) values.Results: Five multicenter studies involving 3,650,434 patients (mean age, 71.1 years) and demonstrating an overall low risk of bias were included. The network analysis indicated that neither alpha-blockers nor 5ARIs were significantly associated with an increased risk of dementia compared with no treatment. However, SUCRA values suggested a relatively higher probability of dementia risk for 5ARIs (finasteride and dutasteride), followed by tamsulosin, doxazosin, terazosin, and alfuzosin.Conclusions: This study found no significant association between the use of alpha-blockers or 5ARIs and increased dementia risk. These findings may assist clinicians in making more informed prescribing decisions, particularly for older male patients with BPH. Further large-scale research with extended follow-up periods is needed to strengthen the evidence across all BPH medications.

News (Medical) associated with Doxazosin Mesylate

05 Feb 2026

·www.biospace.com

IBSA USA Announces FDA Approval of VYBRIQUE™, the First and Only Oral Film to Treat Men with Erectile Dysfunction

Developed with IBSA’s innovative FilmTec ® technology that dissolves in the mouth without the need for food or water Approved in four dosage strengths (25, 50, 75, 100mg) for a tailored therapy to support the patient’s needs Direct home delivery will be available in all states, providing patients a convenient fulfillment option U.S. Commercial availability anticipated in March 2026 Erectile dysfunction affects 30-50 million men in the US and is becoming more prevalent among men under 40 PARSIPPANY, N.J.--(BUSINESS WIRE)--IBSA USA, the U.S. subsidiary of the Swiss pharmaceutical company IBSA, announced today that the Food and Drug Administration (FDA) has approved VYBRIQUE™, the first sildenafil oral film available to treat men aged 18 years and older with erectile dysfunction. Erectile dysfunction (ED) impacts an estimated 30 to 50 million men in the U.S. and becomes more prevalent with age. However, ED is not limited to older populations; cases among younger men are on the rise 1 . This trend highlights the importance of proactive measures, including healthy lifestyle choices and regular physical activity, to help reduce the risk of developing ED 1 . VYBRIQUE is a discreet, easy-to-use, single-dose film that dissolves on the tongue without the need for water or other liquids, providing an on-the-go use option that may be taken anywhere from 30 minutes to 4 hours before sexual activity. VYBRIQUE can be taken with or without food. “While awareness and open discussion around ED have grown, it’s still a sensitive topic where many men value discretion,” said Nicholas Hart, IBSA USA CEO. “The FDA approval of VYBRIQUE provides men experiencing ED with a novel treatment option that helps meet the evolving needs of patients today.” VYBRIQUE was evaluated in a randomized, double-blind, placebo-controlled, flexible-dose study of 475 adult men with ED. Over the 12-week study, participants received VYBRIQUE at doses of 25 mg, 50 mg, 75 mg and 100 mg. The study’s co-primary efficacy endpoints, assessed at Week 4, demonstrated that VYBRIQUE provided superior improvements in sexual function compared to placebo. Additionally, pharmacokinetic analyses showed that peak plasma concentrations were reached between 30 and 300 minutes (median 80 minutes) under fasting conditions. “Beyond age-related factors, research 2 shows that anxiety, depression, and stress can contribute to ED,” said Dr. Ralph Zagha, MD, Principal Investigator, Precision Clinical Research. “Providing a treatment option that is discreet and easy to administer supports men in managing ED in a way that feels approachable and respectful of their sexual health.” IBSA USA is committed to supporting the millions of men affected by ED through filling the treatment gap. For more information on VYBRIQUE, click here. About VYBRIQUE ™ VYBRIQUE (sildenafil) is the first and only FDA-approved oral film for the treatment of erectile dysfunction in adult men in the US. What is VYBRIQUE? VYBRIQUE (sildenafil) oral film is a prescription medicine used to treat erectile dysfunction (ED). VYBRIQUE is not for use in women or children. It is not known if VYBRIQUE is safe and effective in women or children under 18 years of age. IMPORTANT SAFETY INFORMATION VYBRIQUE can cause your blood pressure to drop suddenly to an unsafe level if it is taken with certain other medicines. Do not take VYBRIQUE if you take medicines called nitrates. A sudden drop in blood pressure can cause you to feel dizzy, faint, or have a heart attack or stroke. Do not take VYBRIQUE if you take medicines called guanylate cyclase stimulators, which include riociguat, a medicine that treats pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Do not take VYBRIQUE if you are allergic to sildenafil or any of the ingredients in VYBRIQUE. Tell all your healthcare providers that you take VYBRIQUE. If you need emergency medical care for a heart problem, it will be important for your healthcare provider to know when you last took VYBRIQUE. Stop sexual activity and get medical help right away if you get symptoms such as chest pain, dizziness, or nausea during sex. Sexual activity can put an extra strain on your heart, especially if your heart is already weak from a heart attack or heart disease. VYBRIQUE does not protect you or your partner from getting sexually transmitted diseases, including Human Immunodeficiency Virus (HIV). VYBRIQUE can cause serious side effects including: an erection that will not go away (priapism). If you have an erection that lasts more than 4 hours, get medical help right away because priapism can permanently damage your penis. sudden vision loss in one or both eyes. Sudden vision loss in one or both eyes can be a sign of a serious eye problem called non-arteritic anterior ischemic optic neuropathy (NAION). Stop taking VYBRIQUE and call your healthcare provider right away if you have sudden vision loss in one or both eyes. sudden hearing decrease or hearing loss. Some people may also have ringing in their ears (tinnitus) or dizziness. If you have these symptoms, stop taking VYBRIQUE and contact a healthcare provider right away. Before you take VYBRIQUE, tell your healthcare provider if you: have or have had heart problems such as a heart attack, irregular heartbeat, angina, chest pain, narrowing of the aortic valve or heart failure have had heart surgery within the last 6 months have pulmonary hypertension have had a stroke have low blood pressure, or high blood pressure that is not controlled have a deformed penis shape have had an erection that lasted for more than 4 hours have problems with your blood cells such as sickle cell anemia, multiple myeloma, or leukemia have retinitis pigmentosa, a rare genetic (runs in families) eye disease have ever had severe vision loss, including NAION have bleeding problems have or have had stomach ulcers have liver problems have kidney problems or are having kidney dialysis Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your doctor especially if you take any of the following: nitrates guanylate cyclase stimulators, such as riociguat alpha-blockers, such as doxazosin. The use with VYBRIQUE can lead to a drop in blood pressure or to fainting. HIV protease inhibitors, such as ritonavir and saquinavir oral antifungal medicines, such as ketoconazole and itraconazole antibiotics, such as erythromycin medicines that treat high blood pressure other medicines or treatments for ED The most common side effects of VYBRIQUE are: headache; flushing; upset stomach; stuffy or runny nose; and dizziness. Other side effects include: abnormal vision, such as changes in color vision and blurred vision; back pain; muscle pain; nausea; and rash. These are not all of the possible side effects of VYBRIQUE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-FDA-1088, or contact IBSA Pharma Inc. at 1-800-587-3513. Please see accompanying Full Prescribing Information and Patient Information. About IBSA IBSA ( Institut Biochimique SA ) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrated the 40 th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA’s growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. References 1 Safa A, Waked C. Erectile Dysfunction in Young Adults: A Narrative Review. Cureus. 2025 Aug 12;17(8):e89918. doi: 10.7759/cureus.89918. PMID: 40809937; PMCID: PMC12349891. 2 National Institute of Diabetes and Digestive and Kidney Diseases. (2024, Last Reviewed October 2024 ). Symptoms & Causes of Erectile Dysfunction . U.S. Department of Health and Human Services, National Institutes of Health. Retrieved from PM-1436-EN-v2 Contacts Andrea Cohen, Sam Brown Healthcare Communications andreacohen@sambrown.com , 917-209-7163

Clinical ResultDrug ApprovalAcquisitionPhase 3

16 Sep 2025

·endpoints.news

Exclusive: Fred Hutch duo's startup launches with $10M to build AI generative genomics models

If scientists run enough variations of a lab experiment, perhaps AI models could, someday, predict the results of future versions of that study. A new Seattle-based startup called Synthesize Bio believes it may be able to achieve that sooner than later, starting with gene-expression studies. Synthesize has already generated some promising results in predicting these types of lab experiments, according to a preprint published Tuesday. Synthesize will officially launch on Wednesday, its co-CEOs , Jeff Leek and Robert Bradley, exclusively told Endpoints News, as it releases its AI model, called GEM-1. The 15-employee biotech was founded in 2023 and raised a previously undisclosed $10 million seed round in October 2023, led by Madrona Ventures. Other investors include Sahsen Ventures, AI2 Incubator, Inner Loop Capital, and MD Venture Investments. Leek and Bradley came up with the idea behind Synthesize in the hallways of the Fred Hutchinson Cancer Center. Leek is the cancer center’s chief data officer, and Bradley is the scientific director of a translational data science research center. They wanted to see if biotech could follow a similar trajectory in building large AI models, similar to how companies like OpenAI and Anthropic grew large language models trained on nearly all of the internet’s data. “We felt like this is an idea where we believe it can transform how scientists go about their work,” Bradley said in an interview. The Fred Hutch duo built a model called GEM-1 over the last two years. The model is trained on tons of different gene-expression experiments that they curated and annotated from public datasets. Synthesize is already at work on the next-generation version of the model called GEM-2. “This is the worst version of the GEM model you will ever see,” Leek said. “It’s only going to get better over time.” Gene-expression experiments and single-cell studies have been a hot space within the AI bio field. Large organizations, like the Chan Zuckerberg Initiative and the Arc Institute , are championing moonshot projects that view these types of experiments as key building blocks in eventually making models of virtual cells. Virtual cells could allow more experiments traditionally done in the lab to be accurately simulated by computers. Other startups, like Noetik , Tahoe Therapeutics , and Xaira Therapeutics , are also taking their own twists on building large or rich datasets using some of these experiments. Synthesize believes its model can tackle a wider range of gene-expression experiments than the rest. To test that belief, they looked at how GEM-1’s predictions compared to real-world results. They set a cut-off date of mid-2024, training their model on experimental data in public databases before that date, and then using new experiments added after that date as tests. Overall, Synthesize’s team found GEM-1 “yielded accuracy comparable to the best-possible performance estimated by comparing the results of matched lab experiments,” according to the preprint. The preprint also found that about 95% of these new experiments were similar to those in GEM-1’s training data, meaning the model had already seen experiments that studied similar types of cells or similar perturbations. GEM-1’s predictions varied in accuracy. The model nailed the effect on gene expression of certain molecules, like the hair-loss drug finasteride and an alpha blocker called doxazosin. But predictions for other compounds were less than 50% accurate, like the HIV treatment dolutegravir or cancer drug afatinib, according to the preprint. An area of active research is working on confidence intervals, which could give users a sense of the quality of a prediction. Bradley said that’s something the broader AI field is also working on, as it’s an important problem. That could be critical in telling the finasteride and afatinib predictions apart. “Our goal is not to replace experiments,” Bradley said. “Our goal is to have a seamless blend of wet-lab work and AI experimentation. Experiments are critical. They’re always going to be the gold standard.” Instead, GEM-1 could allow scientists on finite budgets to consider more data for experiments they may not have the time or resources to run. It could also enable scientists to get a sense of results on experiments that are impossible or impractical today, Bradley said. For instance, the model could help predict a drug’s activity in tissue where you can’t take a patient’s biopsy, he said. Leek said there are blind spots, where GEM-1’s performance is wanting. That’s why they are eager to release the model openly, including free access on its website , to gain a sense of how researchers use it and its real-world performance.

21 Jun 2024

·pmlive.com

Study suggests enlarged prostate drugs could protect against dementia with Lewy bodies

Researchers from the University of Iowa (UI) Health Care have suggested that certain drugs used to treat enlarged prostates have the potential to decrease the risk of dementia with Lewy bodies (DLB). Published in Neurology , the study revealed that three enlarged prostate drugs were able to increase the energy production in brain cells. Affecting one in every 1,000 people per year, DLB is the second most common type of dementia, which occurs when protein deposits called Lewy bodies develop in nerve cells in the brain, affecting thinking, memory and movement. Researchers identified more than 643,000 men with no history of DLB who were newly starting one of six drugs used to treat benign prostatic hyperplasia and followed the participants for around three years from when they started taking the medication until they left the database or developed DLB. The observational study found that the already-approved Abbott’s Hytrin (terazosin), Pfizer’s Cardura (doxazosin) and Sanofi’s Uroxatral (alfuzosin) boosted the energy production in brain cells, which could help to slow or prevent neurodegenerative diseases including DLB and Parkinson’s disease (PD), while the three other drugs, tamsulosin and two 5-alpha-reductase inhibitors (5ARIs), finasteride and dutasteride, did not. Men who took terazosin had around a 40% lower risk of developing DLB versus men taking tamsulosin and about a 37% reduction in risk compared to men taking 5ARIs, with no statistically significant difference in risk between men taking tamsulosin and ARIs. “If terazosin and these similar medications can help slow this progression – if not outright preventing the disease – this would be important to preserving cognitive function and quality of life in people with DLB,” said lead study author, Jacob Simmering, UI assistant professor, internal medicine. Previous studies have already linked certain drugs and treatments to other neurodegenerative conditions. In February, researchers from University College London revealed that erectile dysfunction drugs could also be linked to a reduced risk of developing Alzheimer’s disease (AD), the most common form of dementia. Of nearly 270,000 men over the age of 40, those who were prescribed phosphodiesterase 5 inhibitors were 18% less likely to develop AD compared to those who were not.

Clinical ResultDrug Approval

100 Deals associated with Doxazosin Mesylate

External Link

KEGG	Wiki	ATC	Drug Bank
D00608	Doxazosin Mesylate	C02CA04	DB00590

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	Japan	Pfizer Inc.	23 Jan 1990
Hypertension	Japan	Viatris Pharmaceutical GK	23 Jan 1990
Prostatic Hyperplasia	Japan	Pfizer Inc.	23 Jan 1990

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03176693 (CTgov)	Phase 3	Pheochromocytoma	39	Phenoxybenzamine (Phenoxybenzamine)	zrucifkgox(hrknlrhqnt) = yeeniksftc inszrrcwee (aqqjsrbrro, sdjkumkohu - mipazqewxg) View more	-	20 Nov 2023
				Doxazosin (Doxazosin)	zrucifkgox(hrknlrhqnt) = dusurtzcjl inszrrcwee (aqqjsrbrro, eqclwlfqyc - nxkvzafqkv) View more
NCT02500602 (Pubmed \| J Clin Psychiatry)	Phase 2	Alcohol Use Disorder \| Stress Disorders, Post-Traumatic	141	Doxazosin	nioitgaajl(fitmoezvak) = khsfsdqdox zgwmmjyeea (pkfstgvwng )	Negative	08 Mar 2023
				Placebo	nioitgaajl(fitmoezvak) = owrniboaxm zgwmmjyeea (pkfstgvwng )
NCT02500602 (Doxazosin, CTgov)	Phase 2	Alcohol Use Disorder \| Stress Disorders, Post-Traumatic	144	doxazosin (Doxazosin)	pxdfuunwvz(jagiokhtzc) = arkgmssxwc ywqkqinvxk (lrrtafleey, 9.6) View more	-	14 Apr 2021
				placebo (Placebo)	pxdfuunwvz(jagiokhtzc) = wjzrfrsytd ywqkqinvxk (lrrtafleey, 8.7) View more
NCT02989493 (CTgov)	Phase 2	Alcoholism	61	Doxazosin (Doxazosin)	zqvrftfkjk(eikmoroify) = nglffcjkmg csnbfujdae (txorcwhwrl, 20.18) View more	-	18 Mar 2021
				Placebo (Placebo)	zqvrftfkjk(eikmoroify) = jsaqvndlgp csnbfujdae (txorcwhwrl, 23.21) View more
NCT01953432 (CTgov)	Phase 2	Cocaine-Related Disorders	43	Doxazosin (Doxazosin)	callvdbwwi = jfeebeqwvu tbquqpcgrv (boxonsvvbr, jqoxvmvqcz - jazyhiwdht) View more	-	20 Feb 2020
				Placebo (Placebo)	callvdbwwi = ilbdzzzszn tbquqpcgrv (boxonsvvbr, yrxwjhmtes - atrrrzcjfb) View more
NCT00880997 (CTgov)	Phase 1	Cocaine-Related Disorders	35	Placebo	rmvjhfjcan = yblxbahhja resopfxlmr (yhprnvljab, zixnvxnqxm - qhdhmypvej) View more	-	22 Aug 2019
NCT01145183 (CTgov)	Phase 2	Cocaine-Related Disorders	96	Doxazosin (Doxazosin)	cpbycmqcdc = rjrjhrchhe qjyecxkjmf (eifhxiqren, chxzfjdpzj - hcnxopgoxy) View more	-	22 Jul 2019
				Placebo (Placebo)	cpbycmqcdc = xgiyhexdzl qjyecxkjmf (eifhxiqren, pdwxvxodnm - rhtxrbnhcm) View more
NCT00000542 (ALLHAT, Pubmed)	Phase 3	Hypertension ECG LVH \| BP	-	chlorthalidone	eyxbrjqwqp(vwtalzesqg): HR = 1.78 (95% CI, 1.43 - 2.22)	-	16 Apr 2019
				doxazosin
NCT02901977 (Doxazosin-Ramipril, Pubmed \| Blood Press)	Phase 4	Arteriosclerosis	71	Ramipril	kjohjmwwaj(cvdezxanke) = nouopjfivg eyusazapmd (ysvlbastoz ) View more	-	01 Apr 2018
				Doxazosin	kjohjmwwaj(cvdezxanke) = qgwmvdpvcu eyusazapmd (ysvlbastoz ) View more
NCT01730846 (CTgov)	Phase 2	Smoking	35	Placebo	ygtzenhsek(hyvcpjdmms) = usjdkvwebq vfwkjtbpzo (oevpxpoucw, 7.407) View more	-	20 Dec 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis